内镜黏膜下剥离术:西方内镜实践中的适应证与应用
内镜黏膜下剥离术(ESD)本世纪初在日本发展起来,用于为全国筛查项目发现的大量早期胃癌患者提供微创且可治愈的治疗。ESD 整块切除这些早期癌(多数淋巴结转移风险有限),可实现肿瘤完整分期、后续治疗策略分层及潜在治愈。西方内镜医师日益接受 ESD,但持科学谨慎态度。本文对 ESD 在先进内镜组织切除中的作用进行循证批判性评价。
要点
- ESD 在日本发展,用于早期胃癌的微创治愈性治疗。
- ESD 整块切除可完整分期、分层后续治疗并潜在治愈。
- 西方内镜医师日益接受 ESD,但持科学谨慎态度。
核心结论
- 本文对 ESD 在先进内镜组织切除中的作用进行循证批判性评价。
研究设计与样本
- 本文为叙述性综述,未报告系统检索范围。
主要发现
- ESD 本世纪初在日本发展,用于全国筛查项目发现的大量早期胃癌患者的微创治愈性治疗。
- 此前多数此类患者接受手术治疗,费用高且短期和长期并发症风险显著。
- ESD 整块切除这些早期癌(多数淋巴结转移风险有限),可实现肿瘤完整分期、后续治疗策略分层及潜在治愈。
- ESD 改变了浅表黏膜肿瘤内镜治疗的性质,首次使内镜医师能断言早期癌已获确定性治愈。
- 西方内镜医师日益接受 ESD 的治疗可能性,但持科学谨慎态度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endoscopic submucosal dissection was developed in Japan, early in this century, to provide a minimally invasive yet curative treatment for the large numbers of patients with early gastric cancer identified by the national screening program. Previously, the majority of these patients were treated surgically at substantial cost and with significant risk of short- and long-term morbidity. En-bloc excision of these early cancers, most with a limited risk of nodal metastasis, allowed complete staging of the tumor, stratification of the subsequent therapeutic approach, and potential cure. This transformative innovation changed the nature of endoscopic treatment for superficial mucosal neoplasia and, ultimately, for the first time allowed endoscopists to assert that the early cancer had been definitively cured. Subsequently, Western endoscopists have increasingly embraced the therapeutic possibilities offered by endoscopic submucosal dissection, but with some justifiable scientific caution. Here we provide an evidence-based critical appraisal of the role of endoscopic submucosal dissection in advanced endoscopic tissue resection.
引用
- Bourke MJ, Neuhaus H, Bergman JJ, et al. Endoscopic Submucosal Dissection: Indications and Application in Western Endoscopy Practice. Gastroenterology. 2018. PMID: 29486200. doi:10.1053/j.gastro.2018.01.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。